이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Onconetix 관리

관리 기준 확인 0/4

Onconetix's CEO는 Ralph Schiess, Dec2023 에 임명되었습니다 의 임기는 1년 미만입니다. 는 € 38.43K 가치에 해당하는 회사 주식의 1.21% 직접 소유합니다. 38.43K. 경영진과 이사회의 평균 재임 기간은 각각 1.3 년과 1.4 년입니다.

주요 정보

Ralph Schiess

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	1.2%
경영진 평균 재임 기간	1.4yrs
이사회 평균 재임 기간	1.5yrs

최근 관리 업데이트

Recent updates

CEO

Ralph Schiess (45 yo)

less than a year

테뉴어

Dr. Ralph Schiess, Ph D., serves as Chief Science Officer at Onconetix, Inc. since December 15, 2023 and serves as its Interim Chief Executive Officer since January 12, 2024. He Co-founded ProteoMediX AG i...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ralph Schiess	Interim CEO & Chief Science Officer	less than a year	데이터 없음	1.21% $ 39.8k
Karina Fedasz	Interim Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Brian Price	Head of Technology Strategy	3.8yrs	US$126.48k	데이터 없음
Frank Jaeger	Senior VP of Marketing & Business Development	1.4yrs	데이터 없음	데이터 없음
Andrew Skibo	Global Head of Biologics Operations	3.1yrs	데이터 없음	데이터 없음
Theodore Yoho	Head of Business Development	3.1yrs	데이터 없음	데이터 없음
Ali Fattom	Head of Science & Discovery	1.8yrs	데이터 없음	데이터 없음
Jay Newmark	Chief Medical Officer	1.3yrs	데이터 없음	데이터 없음
Christian Bruhlmann	Chief Strategy Officer & GM of Europe	less than a year	데이터 없음	1.06% $ 34.9k
Donald Very	Senior VP of Commercial Research & Development	no data	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: J4T 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
John Rice	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Thomas Meier	Director	less than a year	데이터 없음	데이터 없음
James Sapirstein	Chairman & Lead Independent Director	2.4yrs	US$182.12k	0% $ 0
Ajit Singh	Independent Director	less than a year	데이터 없음	0.014% $ 461.7
Sunetra Gupta	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Simon Tarsh	Independent Director	1.9yrs	US$112.62k	0% $ 0
Timothy Ramdeen	Independent Non-Executive Director	1.5yrs	US$82.67k	0% $ 0

1.5yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: J4T 의 이사회는 경험(평균 재직 기간 1.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Onconetix 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Recent updates

Onconetix, Inc. announced delayed 10-Q filing

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(b)(1)

Onconetix, Inc. announced delayed annual 10-K filing

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech, Inc. Appoints Bruce Harmon as CFO

Blue Water Biotech Receives Non-Compliance Notice from Nasdaq

Blue Water Biotech, Inc. Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech, Inc. Announces Executive Changes

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for Its FDA Approved Products

Blue Water Biotech, Inc. Announces Preliminary Preclinical Data Supporting the Use of Its Norovirus Shell and Plusion Virus-Like Particle Platform to Develop Novel Monkeypox Vaccine Candidate

Blue Water Biotech, Inc. (NasdaqCM:BWV) agreed to acquire Six FDA Approved Drugs from WraSer LLC and Xspire Pharma, LLC.

New major risk - Financial position

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Appoints Frank Jaeger as Senior Vice President of Marketing and Business Development

Blue Water Vaccines Appoints Timothy Ramdeen to Its Board of Directors

High number of new and inexperienced directors

Blue Water Vaccines, Inc. (NasdaqCM:BWV) announces an Equity Buyback for $5 million worth of its shares.

Blue Water Vaccines Announces Appointment of Vuk Jeremic, to Its Board of Directors

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus Pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia At the World Vaccine Congress in Barcelona

CEO, President & Executive Chairman recently sold €2.7m worth of stock

Blue Water Vaccines, Inc. Announces Appointment of Simon Tarsh to Board of Directors

Blue Water Vaccines, Inc. Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

Blue Water Vaccines, Inc. announced that it has received $9.999998 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $9.999998 million in funding

Blue Water Vaccines, Inc., Annual General Meeting, Aug 22, 2022

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC

Blue Water Vaccines, Inc. announced that it has received $7.999411 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $8.000001 million in funding

High number of new and inexperienced directors

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령